Jeff Bohnen

Mr. Jeff Bohnen


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
JBJeff Bohnen
Jeff Bohnen
TWTravis P. Wigstrom
Travis P. Wigstrom
AGAlexis M. Griggs
Alexis M. Griggs
SRStiven Roytman
Stiven Roytman
NPNoah Paalanen
Noah Paalanen
MMMelvin G. McInnis
Melvin G. McInnis
There is growing interest in the investigation of ketogenic diets as a potential therapy for bipolar disorder. The overlapping pharmacotherapies utilized for both bipolar disorder and seizures suggest that a mechanistic overlap may exist between these conditions, with fasting and the ketogenic diet representing the most time-proven therapies for seizure control. Recently, preliminary evidence has begun to emerge supporting a potential role for ketogenic diets in treating bipolar disorder. Notably, some patients may struggle to initiate a strict diet in the midst of a mood episode or significant life stressors. The key question addressed by this pilot clinical trial protocol is if benefits can be achieved with a less restrictive diet, as this would allow such an intervention to be accessible for more patients. Recent development of so-called ketone esters, that once ingested is converted to natural ketone bodies, combined with low glycemic index dietary changes has the potential to mimic two foundational components of therapeutic ketosis: high levels of ketones and minimal spiking of glucose/insulin. This pilot clinical trial protocol thus aims to investigate the effect of a ‘ketogenic-mimicking diet’ (combining supplementation of ketone esters with a low glycemic index dietary intervention) on neural network stability, mood, and biomarker outcomes in the setting of bipolar disorder. Positive findings obtained via this pilot clinical trial protocol may support future target engagement studies of ketogenic-mimicking diets or related ketogenic interventions. A lack of positive findings, in contrast, may justify a focus on more strict dietary interventions for future research.

21 November 2025 in Neurotherapeutics
Verified
Journal Article
Open access
JBJeff Bohnen
Jeff Bohnen
SRStiven Roytman
Stiven Roytman
TWTravis P. Wigstrom
Travis P. Wigstrom
RVRobert K. Vangel
Robert K. Vangel
JBJaime E. Barr
Jaime E. Barr
NBNicolaas I. Bohnen
Nicolaas I. Bohnen
Short-chain fatty acids such as butyrate (key signaling molecules that influence the gut-brain axis and modulate inflammatory, mitochondrial, and transcriptional regulatory processes) are attracting interest as potential treatments for neurodegenerative disorders such as Parkinson's disease. Oral butyrate supplementation in the form of sodium butyrate suffers from limitations, however, as butyrate is rapidly metabolized by colonocytes, resulting in low plasma and brain concentrations. The butyrate prodrug tributyrin, naturally present in butter, is a neutral short-chain fatty acid triglyceride likely to overcome the pharmacokinetic drawbacks of butyrate. Despite these pharmacokinetic advantages, no clinical studies to date have assessed the safety, tolerability, and target engagement of tributyrin as a postbiotic treatment in the setting of Parkinson's disease. Tributyrin's safety profile and potential biomechanistic effects were thus investigated in the setting of Parkinson's disease via an open-label target engagement study. Fourteen individuals with Parkinson's disease and three normal controls completed a 30-day (±7 days) intervention of dietary tributyrin supplementation (500 ​mg taken orally three times daily), demonstrating a reassuring safety profile with high rates of adherence. Ten subjects completed [11C]butyrate PET imaging before and after the intervention to assess for treatment-related changes in brain, liver, heart, and gastrointestinal uptake of butyrate, confirming target engagement (i.e., organ-specific changes in butyrate availability). Systemic anti-inflammatory effects were also observed. Exploratory cognitive, motor, and neurobehavioral clinical testing was conducted before and after the supplementation period, identifying associated improvements in cognitive and motor features of Parkinson's disease. Given these findings, tributyrin warrants further investigation via larger, placebo-controlled trials as a potential complementary therapy for Parkinson's disease.

1 April 2024 in Research Square
Verified
Preprint
Open access
PDF file
TWTravis P. Wigstrom
Travis P. Wigstrom
SRStiven Roytman
Stiven Roytman
JBJeff Bohnen
Jeff Bohnen
RPRebecca R. Paalanen
Rebecca R. Paalanen
AGAlexis Griggs
Alexis Griggs
NBNicolaas I. Bohnen
Nicolaas I. Bohnen
Background With Bipolar Disorder (BD) having a lifetime prevalence of 4.4% and a significant portion of patients being chronically burdened by symptoms, there has been an increased focus on uncovering new targets for intervention in BD. One area that has shown early promise is the mitochondrial hypothesis, with supporting evidence in the form of mtDNA copy number, SNPs, ETC complex activity in peripheral cells, postmortem analyses of ETC function, and iPSC-derived biomarkers, among others. Despite this compelling evidence, at the time of this publication no studies have utilized PET imaging to assess mitochondrial function in the setting of BD. Case Presentation Our participant is a 58 year old male with a past medical history notable for alcohol use disorder and bipolar disorder (unspecified type) who, while enrolled as a control for a separate trial, underwent PET imaging with the mitochondrial complex 1 PET ligand 18F-BCPP-EF. Those images were compared to normal controls which demonstrated significant overlap between areas of dysfunction identified with the 18F-BCPP-EF PET ligand and areas of dysfunction previously identified in the setting of BD with fMRI techniques. That overlap was seen in both affective and cognitive circuits, with mitochondrial dysfunction in the fronto-limbic, ventral affective, and dorsal cognitive circuits showing particularly significant differences. Conclusions Despite mounting evidence implicating mitochondria in BD, this study represents the first PET imaging study to investigate this mechanistic connection. There were key limitations in the form of comorbid alcohol use disorder, limited statistical power inherent to a case study, no sex matched controls, and the absence of a comprehensive psychiatric history. However, even with these limitations in mind, the significant overlap between areas of dysfunction previously demonstrated on fMRI and this 18F-BCPP-EF PET ligand imaging provides compelling preliminary evidence that strengthens the mechanistic link between mitochondrial dysfunction and Bipolar Disorder and warrants further investigation.